- Home
- BRSP vs PHVS Comparison
BRSP vs PHVS Comparison
Compare BRSP & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRSP
- PHVS
- Stock Information
- Founded
- BRSP 2017
- PHVS 2015
- Country
- BRSP United States
- PHVS Netherlands
- Employees
- BRSP N/A
- PHVS N/A
- Industry
- BRSP Real Estate Investment Trusts
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- BRSP Real Estate
- PHVS Health Care
- Exchange
- BRSP Nasdaq
- PHVS Nasdaq
- Market Cap
- BRSP 789.8M
- PHVS 894.8M
- IPO Year
- BRSP 2018
- PHVS 2021
- Fundamental
- Price
- BRSP $6.05
- PHVS $16.49
- Analyst Decision
- BRSP Hold
- PHVS Strong Buy
- Analyst Count
- BRSP 5
- PHVS 5
- Target Price
- BRSP $7.06
- PHVS $41.60
- AVG Volume (30 Days)
- BRSP 924.6K
- PHVS 35.8K
- Earning Date
- BRSP 02-18-2025
- PHVS 04-09-2025
- Dividend Yield
- BRSP 10.58%
- PHVS N/A
- EPS Growth
- BRSP N/A
- PHVS N/A
- EPS
- BRSP N/A
- PHVS N/A
- Revenue
- BRSP $358,805,000.00
- PHVS N/A
- Revenue This Year
- BRSP N/A
- PHVS N/A
- Revenue Next Year
- BRSP N/A
- PHVS N/A
- P/E Ratio
- BRSP N/A
- PHVS N/A
- Revenue Growth
- BRSP N/A
- PHVS N/A
- 52 Week Low
- BRSP $5.07
- PHVS $15.21
- 52 Week High
- BRSP $7.04
- PHVS $28.17
- Technical
- Relative Strength Index (RSI)
- BRSP 62.91
- PHVS 36.48
- Support Level
- BRSP $5.56
- PHVS $17.01
- Resistance Level
- BRSP $6.13
- PHVS $17.94
- Average True Range (ATR)
- BRSP 0.17
- PHVS 0.71
- MACD
- BRSP 0.05
- PHVS -0.09
- Stochastic Oscillator
- BRSP 86.00
- PHVS 17.44
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.